ArticleWorld journal of urology2025
Neurovascular bundle preservation improves postoperative continence recovery in robotic-assisted laparoscopic radical prostatectomy after neoadjuvant hormonal therapy in the treatment of locally advanced prostate cancer: results from a propensity score-matched analysis.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Robot-assisted radical prostatectomy reduces biochemical recurrence risk and improves urinary continence recovery compared with laparoscopic approach in high-risk localized prostate cancer after neoadjuvant therapy: a real-world propensity score-matched analysis.American journal of cancer research · 2026Article
- Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the oncological outcomes and continence recovery of neoadjuvant hormonal therapy (NHT) before robot-assisted laparoscopic radical prostatectomy (RARP) with neurovascular bundle (NVB) preservation in patients with locally advanced prostate cancer (LAPC).
methodsOf the 576 patients with LAPC who underwent RARP during January 2016-March 2024, those who received NHT before RARP with NVB preservation (NVB-RARP) were propensity score (PS)-matched with those undergoing RARP without NVB preservation (NNVB-RARP) based on preoperative and histological characteristics. Clinical and biochemical recurrence results were evaluated post-surgically, and postoperative continence was analyzed in the two groups using Kaplan-Meier curves.
resultsAfter PS matching, each group was matched with 77 patients. When compared with the NNVB-RARP group, the NVB-RARP group did not show any significant difference in the operation time (102.72 ± 11.64 min vs.105.05 ± 16.73 min, p = 0.319), postoperative hospitalization time (5.01 ± 0.80 d vs. 5.21 ± 1.13 d, p = 0.248), intraoperative bleeding (158.43 ± 13.76 mL vs. 161.23 ± 15.15 mL, p = 0.232), pathologic tumor stage (≤ pT2) (53.25% vs. 50.65%, p = 0.747), lymph node status (N1) (27.27% vs. 36.36%, p = 0.226), pathological Gleason score (≥ 8) (81.82% vs. 76.62%, p = 0.427), positive surgical margin (15.58% vs. 20.78%, p = 0.403), or complications (9.10% vs.11.69%, p = 0.597). The NVB-RARP group demonstrated significantly faster continence recovery than the NNVB-RARP group (recovery rates: 1 month 42.86% vs. 16.88%, p < 0.001, 3 months 62.34% vs. 36.36%, p = 0.001, and 12 months 83.12% vs. 66.23%, p = 0.016).
conclusionThe present findings suggest that NHT before RARP with NVB preservation may enhance continence recovery without compromising the oncological outcomes in patients with LAPC.
Indexed as
Identifiers
40887548What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.